Search the Community

Showing results for tags 'wyeth'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • Real estate projects
    • Proposals
    • Going up
    • Completed
    • Mass Transit
    • Infrastructures
    • Cultural, entertainment and sport projects
    • Cancelled projects
  • General topics
    • City planning and architecture
    • Economy discussions
    • Technology, video games and gadgets
    • Urban tech
    • General discussions
    • Entertainment, food and culture
    • Current events
    • Off Topic
  • MTLYUL Aviation
    • General discussion
    • Spotting at YUL
  • Here and abroad
    • City of Québec
    • Around the province of Québec.
    • Toronto and the rest of Canada
    • USA
    • Europe
    • Projects elsewhere in the world
  • Photography and videos
    • Urban photography
    • Other pictures
    • Old pictures

Calendars

There are no results to display.

There are no results to display.

Blogs

There are no results to display.

There are no results to display.


Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Joined

  • Start

    End


Group


About Me


Biography


Location


Interests


Occupation


Type of dwelling

Found 5 results

  1. Pfizer/Wyeth : emplois compromis à Montréal * Dominique Lemoine, Lesaffaires.com * 26 janvier 2009 Wyeth emploie 1200 personnes à Montréal. Photo : Bloomberg Dans la foulée de l’acquisition de Wyeth, Pfizer congédiera 15% de la main-d’œuvre combinée des deux entreprises, soit 19 000 personnes, et fermera cinq usines, selon Bloomberg. Pfizer et Wyeth emploient ensemble 130 000 travailleurs. À Montréal, Wyeth emploie un total de 1 200 personnes répartis dans son usine de fabrication et de distribution, et dans son centre de recherche et de développement de Ville-Saint-Laurent. Environ 600 personnes travaillent pour Pfizer au Québec. La chef des communications et stratégies chez Wyeth Canada, Isabelle Lavoie, a indiqué ne pas encore savoir si des suppressions d’emplois seront effectuées à Montréal. Même chose du côté de Pfizer Canada, où la directrice des communications, Rhonda O’Gallagher, soutient qu’il est trop tôt pour connaître l’impact de l’acquisition sur les activités de Pfizer et de Wyeth au Canada. Selon Bloomberg, Pfizer prévoit que l’expiration du brevet du Lipitor et la mise en marché d’équivalents génériques provoqueront une baisse de 12 milliards de dollars de ses ventes à partir 2011. L’entreprise devra alors réduire de 70% les coûts de Wyeth en recherche, marketing et administration pour garder ses revenus au niveau actuel (2,69 dollars par action) entre 2010 et 2015, selon Tim Anderson, analyste chez Sanford C. Bernstein à New York. «Ce type de décision est nécessaire pour donner de la valeur aux actionnaires de Pfizer», soutient Seamus Fernandez, analyste chez Leerink Swan à Boston. À son arrivée à la tête de Pfizer en juillet 2006, l’actuel chef de la direction, Jeffrey Kindler, avait congédié plus de 15 000 employés en deux ans et fermé cinq centres de recherche. L’acquisition crée une entreprise ayant un revenu annuel d’environ 55% plus élevé que le deuxième plus important fabricant de médicaments au niveau mondial, GlaxoSmithKline.
  2. Wyeth investit 20 M$ à Montréal 28 juin 2007 - 11h42 LaPresseAffaires.com La biopharmaceutique Wyeth Canada, filiale de la compagnie américaine Wyeth (WYE), annonce qu'elle investit 20 M$ dans son usine de Montréal. Cela lui permettra entre autres de rénover et regrouper ses laboratoires dans un seul espace et de mettre la main sur des équipements de production pour le marché international. L'usine est présente à Montréal depuis 1941 et elle emploie plus de 1300 personnes. Raymond Bachand, ministre du Développement économique du Québec, s'est félicité de l'investissement. «Grâce à ce projet, l'usine consolidera son rôle comme fournisseur québécois mondial de produits spécialisés de premier choix en soins de la santé, commente le ministre. Cela va contribuer à renforcer la réputation de Montréal et du Québec comme chef de file dans le secteur biopharmaceutique.» Le titre de Wyeth montait de 1,3% à 57,60 $ US jeudi matin à New York.
  3. Pfizer buying rival drug firm Wyeth for $68B US Unclear how purchase would affect Pfizer facilities in Calgary, Kirkland, Que., Mississauga, Ont. Last Updated: Monday, January 26, 2009 | 11:59 AM ET Comments16Recommend12 The Associated Press Pfizer Inc. is buying rival drug-maker Wyeth in a $68-billion US cash-and-stock deal that will increase its revenue by 50 per cent, solidify its No. 1 rank in the troubled industry and transform it from a pure pharmaceutical company into a broadly diversified health-care giant. At the same time, Pfizer announced cost cuts that include slashing more than 8,000 jobs as it prepares for expected revenue declines when cholesterol drug Lipitor — the world's top-selling medicine — loses patent protection in 2011. The deal announced Monday comes as Pfizer's profit takes a brutal hit from a $2.3- billion legal settlement over allegations it marketed certain products for indications that have not been approved. The New York-based company is also cutting 10 per cent of its workforce of 83,400, slashing its dividend, and reducing the number of manufacturing plants. Canadian impact unknown A spokeswoman for Pfizer Canada Inc. said it was unclear how the round of job cuts would affect the company's domestic operations, which employ more than 1,400 workers at facilities in Calgary, Kirkland, Que., and Mississauga, Ont. "At this time we really aren't aware of any impact on the Canadian organization related to the layoffs that were announced," said Rhonda O'Gallagher in an interview. She suggested that any possible job cuts to the Canadian operations wouldn't be announced for a few weeks or possibly months. Early Monday, Pfizer, the maker of Lipitor and impotence pill Viagra, said it will pay $50.19 US per share under for Wyeth, valuing Madison, N.J.-based Wyeth at a 14.7 per cent premium to the company's closing price of $43.74 Friday. Both companies' boards of directors approved the deal but Wyeth shareholders must do so, antitrust regulators must review the deal and a consortium of banks lending the companies $22.5 billion must complete the financing. Pfizer has been under pressure from Wall Street to make a bold move as it faces what is referred to as a patent cliff in the coming years. As key drugs lose patent protection, they will face generic competition and declining sales. Lipitor is expected to face generic competition starting in November 2011. It brings in nearly $13 billion per year for the company. Diversifying revenues Acquiring Wyeth helps Pfizer diversify and become less-dependent on individual drugs — Lipitor now provides about one-fourth of all Pfizer revenue — while adding strength in biotech drugs, vaccines and consumer products. Wyeth makes the world's top-selling vaccines, Prevnar for meningitis and pneumococcal disease, and co-markets with Amgen Inc. the world's No. 1 biotech drug, Enbrel for rheumatoid arthritis. "The combination of Pfizer and Wyeth provides a powerful opportunity to transform our industry," Pfizer chair and CEO Jeffery Kindler said in a statement. "It will produce the world's premier biopharmaceutical company whose distinct blend of diversification, flexibility, and scale positions it for success in a dynamic global health care environment." Together, the two companies will have 17 different products with annual sales of $1 billion or more, including top antidepressant Effexor, Lyrica for fibromyalgia and nerve pain, Detrol for overactive bladder and blood pressure drug Norvasc. Shortly after announcing the Wyeth deal, Pfizer said fourth-quarter profit plunged on a charge to settle investigations into off-label marketing practices. The company earned $268 million, or four cents a share, compared to profit of $2.72 billion, or 40 cents per share, a year before. Revenue fell four per cent to $12.35 billion from $12.87 billion. Excluding about $2.3 billion in legal charges, the company says profit rose to 65 cents per share. Analysts polled by Thomson Reuters expected profit of 59 cents per share on revenue of $12.54 billion. Looking ahead, New York-based Pfizer expects earnings per share between $1.85 and $1.95 in 2009, below forecasts for $2.49.
  4. Aux grands maux les grands remèdes. Confronté à une érosion de ses ventes, le géant pharmaceutique Pfizer s'est tourné hier vers son concurrent Wyeth et l'a avalé pour 68 milliards US. Une transaction dont l'impact est encore difficile à mesurer au Québec, où les deux entreprises emploient conjointement environ 1800 personnes. Pour en lire plus...
  5. Quelques jours après la fusion de Pfizer et de Wyeth, le mouvement de fusion dans le secteur pharmaceutique se poursuit avec l'achat par Merck de son concurrent Shering-Plough. Pour en lire plus...